HIV Viral Rebound Due to a Possible Drug-Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases

Authors

S. Lena Kang-Birken, University of the PacificFollow
Dena El-Sayed, University of the Pacific
John Prichard, University of the Pacific

Document Type

Article

Publication Title

Journal of the International Association of Providers of AIDS Care (JIAPAC)

ISSN

2325-9582

Volume

18

DOI

10.1177/2325958218821653

First Page

1

Last Page

4

Publication Date

1-1-2019

Abstract

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a potent fixed-dose, once-daily regimen for HIV-1 treatment and has rare emergence of drug resistance. We report a potential drug-drug interaction in 2 female patients both receiving treatment for HIV and cerebral toxoplasmosis: one case between E/C/F/TAF with calcium carbonate and a second case involving leucovorin as calcium salt. Both cases resulted in rise in HIV RNA levels and emergence of M184 V mutation and resistance to elvitegravir and raltegravir. To the best of our knowledge, these 2 cases are the first reports of rapid emergence of mutation from coadministration of E/C/F/TAF and calcium.

Recommended Citation

Kang-Birken, S. L., El-Sayed, D., & Prichard, J. (2019). HIV Viral Rebound Due to a Possible Drug-Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases. Journal of the International Association of Providers of AIDS Care (JIAPAC), 18, 1–4. DOI: 10.1177/2325958218821653
https://scholarlycommons.pacific.edu/phs-facarticles/377

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.